Here’s a bold statement: the future of rheumatology might just be found in weight-loss drugs. But here’s where it gets controversial—could these medications, traditionally used for metabolic health, revolutionize how we treat conditions like gout and rheumatoid arthritis? Let’s dive in.
Exciting findings from ACR Convergence 2025 shed light on the expanding role of metabolic therapies in rheumatology. And this is the part most people miss—novel anti-obesity medications (AOMs) like semaglutide and tirzepatide aren’t just helping patients shed pounds; they’re also significantly lowering serum urate levels in those with gout and baseline hyperuricemia. This dual benefit could be a game-changer for millions.
Researchers analyzed data from Mass General Brigham (MGB), a leading not-for-profit health system in Greater Boston. MGB operates two prestigious academic medical centers—Massachusetts General Hospital and Brigham and Women’s Hospital—alongside specialty hospitals, community care, and a licensed health plan serving Massachusetts and southern New Hampshire. By examining the electronic health records of 22 patients with gout and hyperuricemia, they uncovered a striking correlation: for every kilogram of weight lost, serum urate levels dropped by 0.13 mg/dL. Patients who lost more than 10% of their body weight saw an even more dramatic reduction—2.36 mg/dL more than those who lost less than 5%.
Here’s the kicker: these findings suggest that AOMs could be a powerful multi-purpose tool for patients battling both gout and obesity. But is this enough to convince skeptics? Larger-scale studies are needed to confirm this hypothesis, but the potential is undeniable.
At ACR Convergence 2025, GLP-1 receptor agonists and SGLT2 inhibitors stole the spotlight. Dr. Shreya Sakthivel’s retrospective study explored their impact on rheumatoid arthritis (RA) flares in patients on DMARD therapy. Using real-world data from the TriNetX research network, the study compared three groups: DMARDs alone, DMARDs plus SGLT2 inhibitors, and DMARDs plus GLP-1 agonists. The results? SGLT2 inhibitors were linked to a significant reduction in RA flares, while GLP-1 agonists showed a non-significant trend toward improvement. But here’s the question: Could GLP-1 therapies, already known for their cardiometabolic benefits, also modulate disease activity in autoimmune conditions?
Dr. Sakthivel believes so, highlighting their potential as dual-action agents. Yet, this interpretation isn’t without controversy. Critics argue that higher baseline RA severity in the GLP-1 group might skew results, calling for more research. What do you think? Are we on the cusp of a metabolic revolution in rheumatology, or is this just another overhyped trend?
ACR Convergence 2025, held in Chicago from October 24-29, has certainly sparked the debate. As we await further studies, one thing is clear: the intersection of metabolic health and rheumatic disease is a frontier worth exploring. What’s your take? Let’s discuss in the comments!
